| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.054 | 0.8 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |